Cegedim (ALCGM) AI Stock Analysis

• Market Cap: €188.57M
• Dividend Yield: N/A
• Average Volume (3M): 11.58K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.41
• Revenue Growth: 3.79%
• EPS Growth: -797.10%
• Country: FR
• Employees: 6,605
• Sector: Technology
• Sector Strength: 88
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.10
• Shares Outstanding: 14,097,155
• 10 Day Avg. Volume: 10,897
• 30 Day Avg. Volume: 11,578
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €14.00
• Price Target Upside: 29.63% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: €14.50 ▲(34.26% Upside)

Cegedim's overall stock score is primarily influenced by its solid revenue growth and strong technical momentum. However, challenges with profitability, financial stability, and valuation concerns due to a negative P/E ratio and lack of dividend yield weigh down the score. The absence of earnings call data and corporate events means these factors did not influence the score.

Positive Factors

Consistent Revenue Growth

Steady top-line growth indicates durable demand for Cegedim's healthcare software and data services, supporting recurring subscription and transaction revenues. Over 2-6 months this trend underpins investment in product development and preserves commercial momentum across payer, pharma and provider clients.

Diversified Revenue Streams & Partnerships

A mix of subscription licensing, transaction/data fees and consulting reduces reliance on any single revenue source, improving resilience. Strategic partnerships with pharmaceutical firms and insurers strengthen sales channels, enhance credibility, and support long-term contract renewal dynamics.

Strong Operating Cash Flow Generation

Robust operating cash flow signals good cash conversion from operations despite accounting losses, enabling funding for R&D, working capital and debt servicing. This cash quality is a durable strength that can support strategic investments or deleveraging over the medium term.

Negative Factors

Negative Net Income & Margin Pressure

Sustained net losses and falling EBIT margins erode profitability and limit internal funding capacity. If cost structures and operational efficiencies aren't corrected, the company may face constrained ability to invest in growth initiatives or improve returns, affecting long-term competitiveness.

Balance Sheet & Equity Weakening

A higher debt load alongside falling equity reduces financial flexibility and increases refinancing risk. This weaker balance sheet can limit strategic options, raise borrowing costs, and make the firm more vulnerable to cash flow shocks over the coming months if deleveraging doesn't occur.

Volatile and Declining Free Cash Flow

Unstable free cash flow constrains the company's ability to sustain capital expenditures, R&D or pursue M&A without external financing. Persistent FCF volatility increases reliance on debt or equity raises, which can dilute returns and complicate multi-quarter strategic planning.

Cegedim Business Overview & Revenue Model

Company Description

Cegedim SA operates as a technology and services company in the field of digital data flow management for healthcare ecosystem and B2B in France, rest of Europe, and internationally. It operates through Health Insurance, HR and E-Services; Healthcare Professionals; and Cloud & Support segments. The Health Insurance, HR and E-Services segment markets various products and services to insurance companies, mutual insurers, personal protection insurers, and insurance brokers, as well as engages in the interactions between these entities and healthcare professionals. This segment also provides solutions for IT services and hosting, digitization, human resources and payroll management outsourcing, electronic data exchange, and data processing services. The Healthcare Professionals division sells management software, databases, and solutions to doctors, paramedical professionals, pharmacists, and healthcare facilities. It also operates as a business software publisher for healthcare and insurance professionals. The company was incorporated in 1969 and is headquartered in Boulogne-Billancourt, France. Cegedim SA is a subsidiary of FCB SAS.

How the Company Makes Money

Cegedim generates revenue through multiple streams, primarily by providing software solutions and data services to healthcare organizations and pharmaceutical companies. Key revenue models include subscription fees for software licenses, transaction fees for data services, and consulting fees for strategic advisory services. Cegedim also benefits from partnerships with major healthcare stakeholders, including pharmaceutical firms and insurance companies, which enhance its market reach and credibility. Additionally, the company may earn revenue through research and development contracts, leveraging its expertise in healthcare analytics and technology.

Cegedim Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Cegedim Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALCGM, the sentiment is Positive. The current price of 10.8 is below the 20-day moving average (MA) of 13.62, below the 50-day MA of 13.05, and below the 200-day MA of 11.44, indicating a bullish trend. The MACD of 0.19 indicates Positive momentum. The RSI at 57.68 is Neutral, neither overbought nor oversold. The STOCH value of 19.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALCGM.

Cegedim Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EQS	74 Outperform	€613.59M	16.91	16.40%	2.85%	4.45%	-14.08%
ALKEY	62 Neutral	€123.23M	9.05	―	―	-4.16%	―
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
ALCGM	60 Neutral	€188.57M	-13.32	-5.21%	―	3.79%	-797.10%
AL2SI	45 Neutral	€271.57M	127.41	―	―	―	―
CLA	44 Neutral	€81.23M	-23.93	―	―	-0.95%	49.19%